ondansetron + meloxicam

**Ondansetron + meloxicam** is a fixed-dose combination of two small-molecule pharmaceuticals: ondansetron, a selective serotonin 5-HT3 receptor antagonist that prevents nausea and vomiting by blocking serotonin effects in the gut and central nervous system, primarily used for chemotherapy-, radiotherapy-, and postoperative-induced emesis; and meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-2 (COX-2) preferentially over COX-1 to reduce inflammation, pain, and fever. This combination lacks a unique brand name and is not a standard marketed product but may be used empirically for multimodal symptom control, such as postoperative pain with nausea or chemotherapy-related symptoms, leveraging ondansetron's antiemetic action and meloxicam's analgesic/anti-inflammatory effects. No specific developers or primary indications are established for this pairing, and interactions between the components are unlikely based on their metabolic profiles.[1][2][7]